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Abstract
Background: Outbreaks of infectious diseases generate outbreaks of scientific evidence. In 2016 epidemics of Zika
virus emerged, and in 2020, a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a
pandemic of coronavirus disease 2019 (COVID-19). We compared patterns of scientific publications for the two
infections to analyse the evolution of the evidence.
Methods: We annotated publications on Zika virus and SARS-CoV-2 that we collected using living evidence
databases according to study design. We used descriptive statistics to categorise and compare study designs over
time.
Results: We found 2286 publications about Zika virus in 2016 and 21,990 about SARS-CoV-2 up to 24 May 2020, of
which we analysed a random sample of 5294 (24%). For both infections, there were more epidemiological than
laboratory science studies. Amongst epidemiological studies for both infections, case reports, case series and cross-
sectional studies emerged first, cohort and case-control studies were published later. Trials were the last to emerge.
The number of preprints was much higher for SARS-CoV-2 than for Zika virus.
Conclusions: Similarities in the overall pattern of publications might be generalizable, whereas differences are
compatible with differences in the characteristics of a disease. Understanding how evidence accumulates during
disease outbreaks helps us understand which types of public health questions we can answer and when.
Background
Scientists publish their findings to understand epidemics
caused by novel pathogens. This evidence will guide de-
cisions, actions and interventions to mitigate the effects
of the disease through policy, programmes, guidelines
and further research [1]. Two viral pathogens that have
caused epidemics across a large number of countries
since 2016 resulted in the declaration of a Public Health
Emergency of International Concern (PHEIC) by the
World Health Organization (WHO) Director-General
[2]. Zika virus, a mosquito-borne virus caused epidemics
of microcephaly that were first noticed in late 2015 in
Brazil, although it was first discovered in 1947 and had
caused small outbreaks of infection before then [3]. Se-
vere acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), was first discovered in January 2020 as the
cause of a new zoonotic disease, coronavirus disease
2019 (COVID-19), spread primarily through the
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respiratory route [4]. There are marked differences in
the natural history of the two diseases, where micro-
cephaly caused by Zika virus infection only emerges
months after infection, COVID-19 occurs acutely. Inten-
sive research efforts for both infections were catalysed
by the needs of national, regional and global health
agencies to answer key questions on transmission, pre-
vention, and interventions at the individual and commu-
nity level [5]. During the SARS-CoV-2 pandemic, the
accumulation of peer-reviewed and preprint publications
has been vast; from April, 2020 onwards, an average of
2000 scientific publications appeared per week. A simi-
lar, albeit smaller surge in publications occurred in 2016
during the Zika virus epidemic. The sudden large in-
creases in publications about these conditions over a
short time can also be described as outbreaks.
The emergence of a new disease provides an oppor-
tunity to examine how research evidence emerges and
develops, according to the research question and the
feasibility of the study methods. Hierarchies of evidence
are often used to rank the value of epidemiological study
designs, prioritising experimental methods, but these do
not take account of purposes, other than the effects of
interventions. Anecdotal observations allow for the dis-
covery and description of phenomena, studies with com-
parison groups are more appropriate to test hypotheses,
and randomised trials test the causal effects of interven-
tions [6]. Early on in the Zika epidemic, questions about
causality were important because the link between clus-
ters of babies born with microcephaly and Zika virus in-
fection was not obvious; congenital abnormalities caused
by a mosquito-borne virus had never been reported. In
an earlier analysis of 346 publications about Zika virus
alone, we described the temporal sequence of publica-
tion of types of study to investigate causality [7]. Others
have assessed the accumulation of study designs over
time during the SARS-CoV-2 outbreak and concluded
that early in the outbreak, simple observational studies,
mathematical modelling studies and narrative reviews
were most abundant [8, 9]. Here, we proposed a hypo-
thetical sequence: first, anecdotal observations are re-
ported in case reports or case series. Analytical
observational studies follow. In parallel, basic research
studies investigate the biology and pathogenesis of the
disease. Mathematical modelling can provide evidence
where direct observations are not available [10]. After a
delay, controlled trials examining interventions are
published.
The emergence of SARS-CoV-2 allows a comparison
with Zika virus between the timing and types of evidence
published at the start of an outbreak of a new disease.
The objectives of this study were to analyse the patterns
of evolution of the evidence over time during the 2016
Zika virus epidemic and the 2020 SARS-CoV-2
pandemic. We compare the sequence of evidence accu-




We used databases that were created for the Zika Open
Access Project (ZOAP) [11] and COVID-19 Open Ac-
cess Project (COAP) [12]. Both databases are maintained
by the authors and are used to conduct living systematic
reviews [13, 14]. For each pathogen, we ran daily auto-
mated searches to index and deduplicate records of arti-
cles about Zika virus (from January 1, 2016) and SARS-
CoV-2 research (from January 1, 2020) in EMBASE via
OVID, MEDLINE via PubMed, and the preprint server
bioRxiv (for SARS-CoV-2 we also searched medRxiv).
These data have been collected and deduplicated daily
for several living systematic reviews and detailed meth-
odology is described elsewhere [11, 13–16]. We specify
the search terms in the Additional file 1 Text 1.
Annotation of records with study design
We screened the title and abstract, or full text when the
first was insufficient, and annotated each record with its
study design. For weeks where the volume SARS-CoV-2
of research was over 400 publications, starting mid-
March, we drew a random sample of 400 publications
with the R ‘sample’ function, without replacement. The
number of selected publications was a pragmatic deci-
sion that balanced an adequate sample size and manage-
able workload for the number of crowd-volunteers. The
annotation of the Zika virus dataset was performed for
previous systematic reviews (from January 1, 2016 to De-
cember 31, 2016) [13, 15]. We first classified publica-
tions into the broad groups “epidemiology” or “basic
research”, “non-original” articles (editorials, viewpoints,
and commentaries) and “other”. These are groups that
we used in an earlier study about Zika virus [7], so for
this comparative study, we applied them to the publica-
tions about SARS-CoV-2. We subdivided epidemio-
logical and basic research further, based on their study
design. We provide details on the classification of the
study designs in the Additional file 1 Table S1 and in an
online annotation guide [17].
Crowd
To distribute the annotation workload, we recruited a
‘crowd’ of volunteer scientists [18]. We included re-
searchers with a background in medicine or public
health, who qualified by passing a pilot test using an on-
line tool that simulates classification tasks. A demonstra-
tion and the source code of the tool are provided online
[19].
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The crowd members used another online tool for
screening, annotation, and verification of each record. A
first crowd member screened and annotated a record,
and a second crowd member verified the annotated data.
Disagreements were resolved by a third member of the
team. One person (MJC) distributed tasks centrally and
a ‘crowd supervisor’ (AMI) monitored progress. Crowd
members took part in the interpretation of the results.
Reported number of cases
To compare the number of publications against the
number of reported cases, we used open-source data on
Zika virus and SARS-CoV-2 from https://github.com/
andersen-lab/zika-epidemiology/tree/master/paho_case_
numbers and https://ourworldindata.org/covid-cases.,
see Availability of data and materials.
Date that a publication becomes available
We defined the date at which a publication became
available as the date it was indexed in the MEDLINE or
EMBASE database, or when it appeared on the preprint
server.
Data analysis
First, we described the evolution of reported cases and
publications over time. Second, we described the propor-
tions of study designs, by week, for SARS-CoV-2 and by
month for Zika virus, due to the differences in research
volume. We omitted the first two weeks of 2020 for
SARS-CoV-2 because there were only four publications,
making the proportions unstable. To take into account
the random sampling of the SARS-CoV-2 research, we
provided the Wilson score 95% confidence intervals (CI)
for the proportions. Third, we quantified the timing and
speed of the accumulation of publications of different
study designs: We plotted the time elapsed between the
first and twentieth occurrence of publications of each
study design. Last, we described the proportion of evi-
dence that was published on preprint servers during the
two epidemics, and by study design. All analyses were
conducted in R 4.0.1 [20].
Results
Between week one and week 21 (up to May 24) 2020, we
indexed 21,990 publications, and a crowd of 25 contrib-
utors annotated a sample of 5294 (24%) publications on
SARS-CoV-2. For the Zika virus research, we annotated
all 2286 identified publications for 2016. Both the vol-
ume of the weekly reported cases and number of publi-
cations were 30–50-fold higher for SARS-CoV-2 than
for Zika virus (Fig. 1).
The proportion of different study designs
In both epidemics, a substantial and reasonably stable
proportion of the publications were non-original re-
search. The overall proportion of non-original publica-
tions was higher for Zika virus (55%, (Additional file 1
Table 2)) than for SARS-CoV-2 (34% [95% CI: 33–35],
(Additional file 1 Table 3)). For publications of original
research, the proportion of basic research publications
increased over time for Zika virus, but decreased for
SARS-Cov-2 research (Fig. 2a).
Within the epidemiological study designs, mathemat-
ical modelling studies had a larger role at the beginning
of the SARS-CoV-2 pandemic (10.1%, [95% CI: 9.3–
11.0]) and compared to the Zika virus outbreak (3.2%).
Many of these were published as preprint publications.
When we excluded preprint publications, the evolution
of evidence over time became more similar between the
two epidemics (Additional file 1 Fig. 2). Case reports
and case series accounted for approximately 10% of the
total body of evidence; 10.7% [95% CI: 9.9–11.6] for
SARS-CoV-2 and 9.7% for Zika virus research. Analytical
epidemiological study designs became more prevalent
Fig. 1 The global number of reported cases (a), and the number publications (b) by week for SARS-CoV-2 infections in 2020 and Zika virus
infections (ZIKV) in 2016. In panel B, the dashed grey boxes contain the period and number of publications for which the study design was
annotated. The vertical scales differ for each infection. SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2
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later in the SARS-Cov-2 and Zika virus epidemics. Case-
control and cohort studies accounted for 4.0% [95% CI:
3.5–4.6] for SARS-CoV-2 and 0.8% for Zika virus. Trials
also emerged later but in smaller numbers (27/5294 for
SARS -CoV-2, and 1/2286 for Zika virus) (Fig. 2b).
Accumulation of epidemiological and basic research
Despite the difference in volume, the accumulation of
study designs over time for SARS-CoV-2 and Zika virus
research show some similarities (Fig. 3). Case reports,
case series and cross-sectional studies were the first
epidemiological study designs to be reported, together
with non-original articles and reviews. Case-control and
cohort studies followed later; this delay was more prom-
inent in the Zika virus research. Phylogenetic studies
and mathematical modelling studies had a more promin-
ent role early on during the SARS-CoV-2 pandemic than
in the Zika virus epidemic. In vivo and in vitro labora-
tory studies followed between case reports and con-
trolled observational studies. Trials were the last type of
study to be published. This pattern of accumulation did
Fig. 2 Proportions of different study designs of published research on SARS-CoV-2 (SARS-CoV-2) and Zika virus (Zika virus) over time. Epidemiological,
basic, and “non-original” research (a); epidemiological research by study design (b). For display purposes SARS-CoV-2 data is shown by week and Zika
virus data by month. SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; PHEIC: Public Health Emergency of International Concern
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not change when we did the same comparison but with-
out preprint publications (Additional file 1 Fig. S3).
The role of preprint publications
The role of preprint publications was more prominent at
the start of the SARS-CoV-2 pandemic than the Zika
virus epidemic. In January and February 2020, the ma-
jority of publications on SARS-CoV-2 were manuscripts
on preprint servers (Fig. 4a). Basic research reviews were
seldom published on preprint servers, whereas 77% of
the mathematical modelling studies were initially made
available on preprint servers (Fig. 4b). The proportion of
modelling and sequencing studies that were published as
preprints was high throughout the first 21 weeks of
2020, whereas other designs reduced over time (Add-
itional file 1 Fig. S4). The proportion of preprints de-
creased over time.
Fig. 3 Time to the first 20 publications in a study design, for SARS-CoV-2 infections (SARS-CoV-2) and Zika virus infections (Zika virus). SARS-CoV-2:
Severe acute respiratory syndrome coronavirus 2; PHEIC: Public Health Emergency of International Concern
Fig. 4 The proportion of preprint publications and peer-reviewed publications for SARS-CoV-2 (SARS-CoV-2) and Zika virus (Zika virus) research
over time (a) and by study design for SARS-CoV-2 (b). SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2
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Discussion
The overall distribution of publications at the start of
the SARS-CoV-2 and Zika virus epidemics was similar.
Epidemiological research was more commonly published
than laboratory research and non-original contributions
accounted for a substantial fraction of all publications
for both infections. For both infections, case reports and
case series, mathematical modelling and phylogenetic
studies were prominent at the start of the epidemic,
whereas analytical study designs, such as cohort and
case-control studies, appeared later. Trials emerged later
and accounted for a small proportion of all studies. The
volume and speed of evolution were much higher for
SARS-CoV-2 than for Zika virus. Modelling studies were
more prominent and basic research studies were less
common for SARS-CoV-2 than for Zika virus. More
studies were published as preprints for SARS-CoV-2,
but this proportion declined over time.
Strengths and limitations
Strengths of this study include the comparable and re-
producible search strategies for two emerging infectious
diseases and categorisation of study design by a volun-
teer crowd of epidemiologist reviewers. A limitation is
that the design of an epidemiological study is not always
clear, and different scientists might classify the same
study differently. We tried to tackle this limitation by
screening and training of the volunteer scientists, verifi-
cation of decisions and having a third person resolving
disagreements [12]. There are other limitations. First, we
only recorded the study design of publications and did
not assess the content or its methodological quality. To
trace the evolution of evidence for specific research
questions, in-depth studies are needed. Second, for
SARS-CoV-2, the volume of publications meant that we
only annotated a sample of records. The total in the first
5 months of the pandemic was, however, higher than for
1 year of publications about Zika virus and the propor-
tions of different study designs for Zika virus stabilised
quickly. Third, the searches do not include all sources of
peer-reviewed evidence or preprint sources. Incomplete-
ness of the evidence base should not affect our conclu-
sions as long as other sources account for a stable
proportion of publications.
We followed two dimensions of the publication of evi-
dence about two newly emerging infectious diseases; the
overall distribution of publication types and changes
over time. Similarities in the overall distribution of epi-
demiological, basic science and non-original publications
for SARS-CoV-2 and Zika virus could reflect patterns of
the overall trajectory of research about emerging infec-
tious diseases. In the initial phase of an outbreak with a
novel pathogen, case reports and case series predomin-
ate. These types of study describe and refine the clinical
characteristics of the disease [21]. Observations from
these studies are commonly used to define research
questions and formulate hypotheses about various as-
pects of transmission and disease. More formal,
hypothesis-driven and interventional research follows
later [6].
The differences between study designs in the two epi-
demics are compatible with differences in characteristics
of the diseases. The higher proportion of basic research
in Zika virus research may have several explanations.
First, the occurrence of congenital abnormalities follow-
ing a vector-borne infection was poorly understood;
in vivo and in vitro studies were essential to investigate
in utero transmission and mechanisms for neurotoxicity
and neuropathology [22]. Second, the establishment of
mouse models was more successful in Zika virus re-
search than for SARS-CoV-2 research, [23] although ef-
forts are ongoing [24]. Third, the later occurrence of
case-control studies and cohort studies in Zika virus,
might be caused by the delay to congenital outcomes,
compared to the shorter delay in outcomes caused by
SARS-CoV-2. Fourth, the prominent role of mathemat-
ical modelling studies during the beginning of the
SARS-CoV-2 pandemic, probably reflects early recogni-
tion of the pandemic potential and the need for forecasts
of the global spread. Mechanistic models describing the
transmission SARS-CoV-2 are also less complex than for
arboviruses like Zika virus, allowing many to explore
transmission dynamics [10]. The higher volume of ob-
servational research about SARS-CoV-2 research could
reflect both the 50-fold higher numbers of cases than for
Zika virus and the severity of the pandemic, whereas
Zika virus was largely limited to the Americas and cases
of infection were already declining as the research vol-
ume started to increase. The increasing role of preprints
during the SARS-CoV-2 coincided with developments in
open access publishing and the need for speedy access
to outbreak research [25]. The increase of preprint pub-
lishing results in faster access to evidence, which will
benefit the public health response. The rapid pace of
publication in both preprint and peer-reviewed publica-
tions mean that readers need to carefully appraise the
methodological quality of the research.
Other researchers have studied the evolution of evi-
dence during disease outbreaks as well. During the SARS
outbreak in 2003, Xing et al. (2010) described epidemio-
logical studies from Toronto and Hong Kong [26],
whereas we included epidemiological and non-
epidemiological articles all over the world. Xing and col-
leagues primarily studied the publication time delay dur-
ing the outbreak and concluded that only a minority
(7%) of the publications was published during the time
outbreak, while we investigated the proportion of the
preprints over peer-reviewed publications [26]. For the
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SARS-CoV-2 pandemic, Liu et al. (2020) performed a
bibliometric analysis of the SARS-CoV-2 literature up to
March 24, 2020 [27], classifying research by theme, ra-
ther than by study design. They observed that clinical
features of the COVID-19 were studied heavily, whereas
other research areas such as mental health, the use of
novel technologies and artificial intelligence, and patho-
physiology remained underexplored. In contrary to the
manual annotation of our project, Tran et al. (2020) per-
formed automatic Latent Dirichlet allocation topic mod-
elling of publications on SARS-CoV-2, published up to
April 23, 2020 [28], with findings similar to those of Liu.
et al. [27]. While we validated classification of study de-
sign manually, Tran et al. did not describe a validation
of their automated modelling method. Jones et al.
(2020), who classified study designs using categories
comparable to ours, showed a similar pattern of study
design occurrence during the early SARS-CoV-2 pan-
demic, where case reports and narrative reviews were
found to be most published [8]. However, they merely
present absolute numbers and a comparison with other
outbreaks is absent [8]. Similarly, Fidahic et al. (2020)
concluded that early in the SARS-CoV-2 pandemic arti-
cles were predominantly retrospective case reports and
modelling studies [9]. Haghani and Bliemer (2020) com-
pared SARS, MERS and SARS-CoV-2 literature and
showed that around 50% of studies were non-original,
which is in line with our results [29]. Unlike our
categorization method, Haghani and Bliemer used the
categorization by the citation database ‘SCOPUS’ and
conclude that the studies linked to public health re-
sponse are first to emerge .
Our work has several implications for public health
policy and research. The change over time in the types
of studies has particular implications for synthesis of evi-
dence and for public health as more research is pub-
lished. Policy makers and public health practitioners
need to keep up with rapid changes in the state of
the evidence, because these changes affect recommen-
dations for control measures. For example, preprint
publication in December 2020, about the spread of
new more infectious variants of SARS-CoV-2 in the
United Kingdom and South Africa [30], provided the
scientific evidence for strengthening control measures
in several European Countries and changing vaccin-
ation policy in South Africa. The earliest studies pub-
lished might not be the most appropriate to answer
specific questions, for example, about causality [31],
or to quantify disease characteristics. Triangulation of
different sources of evidence using frameworks, such
as those based on the Bradford Hill criteria [15], and
careful interpretation through explicit acknowledg-
ment of limitations can help. Living systematic re-
views are particularly useful because changes to
inclusion criteria can be planned and protocols can
be amended in advance of an update. For example,
quantifying the proportion of asymptomatic SARS-
CoV-2 infections in March 2020 relied largely on de-
scriptions from contact investigations in single fam-
ilies [32]. By June 2020, there were also studies at
lower risk of selection and measurement biases, such
as population screening .
The vast quantity of evidence about emerging infec-
tions poses challenges for the efficient handling and
evaluation of information. The speed with which the evi-
dence about SARS-CoV-2 has accumulated is unprece-
dented. We recruited a large team of experienced
scientists, but we were still not able to categorise all
publications by the time this manuscript is written. Ma-
chine learning methods, such as natural language pro-
cessing, to classify text is a promising approach for the
triage of publication types [18]. We also see potential in
a scaled-up version of collaborative crowd-sourcing
among experts in the field, to increase efficiency and
avoid research waste [33]. The technical tools to manage
such efforts are available, but guidelines on how to best
conduct the live synthesis of evidence should be devel-
oped and evaluated further [34].
Conclusions
The findings of this study show how description of the
types and timing of publications during outbreaks of
emerging and re-emerging diseases can help us under-
stand which types of public health questions we can an-
swer and when. Further analyses of the generation and
accumulations of research evidence during disease out-
breaks could help to improve the public health response.
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